The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
Open accessAbstract
Purpose: Colon cancers exhibiting DNA mismatch repair (MMR) defects demonstrate distinct clinical and pathologic features, including better prognosis and reduced response to fluorouracil (FU) –based chemotherapy. This prospective study investigated adjuvant chemotherapy containing FU and irinotecan in patients with MMR deficient (MMR-D) colon cancers. Patients and Methods: Cancer and Leukemia Group B 89803 randomly assigned 1,264 patients with stage III colon cancer to postoperative weekly bolus FU/leucovorin (LV) or weekly bolus irinotecan, FU, and LV (IFL). The primary end point was overall survival; disease-free survival (DFS) was a secondary end point. Tumor expression of the MMR proteins, MLH1 and MSH2, was determined by immunohistochemistry (IHC). DNA microsatellite instability was also assessed using a panel of mono- and dinucleotide markers. Tumors with MMR defects were those demonstrating loss of MMR protein expression (MMR-D) and/or microsatellite instability high (MSI-H) genotype. Results: Of 723 tumor cases examined by genotyping and IHC, 96 (13.3%) were MMR-D/MSI-H. Genotyping results were consistent with IHC in 702 cases (97.1%). IFL-treated patients with MMR-D/MSI-H tumors showed improved 5-year DFS as compared with those with mismatch repair intact tumors (0.76; 95% CI, 0.64 to 0.88 v 0.59; 95% CI, 0.53 to 0.64; P = .03). This relationship was not observed among patients treated with FU/LV. A trend toward longer DFS was observed in IFL-treated patients with MMR-D/MSI-H tumors as compared with those receiving FU/LV (0.57; 95% CI, 0.42 to 0.71 v 0.76; 95% CI, 0.64 to 0.88; P = .07; hazard ratio interaction between tumor status and treatment, 0.51; likelihood ratio P = .117). Conclusion: Loss of tumor MMR function may predict improved outcome in patients treated with the IFL regimen as compared with those receiving FU/LV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Microsatellite Instability in Cancer of the Proximal Colon
Thibodeau, S. N., Bren, G., & Schaid, D. (1993) · Science · doi:10.1126/science.8484122 · Cited by 3,130
Ionov, Y., Peinado, M. A., Malkhosyan, S., Shibata, D., & Perucho, M. (1993) · Nature · doi:10.1038/363558a0 · Cited by 2,708
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Self-citationGenetic instability in colorectal cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/386623a0 · Cited by 1,986
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Tumor Microsatellite Instability and Clinical Outcome in Young Patients with Colorectal Cancer
Gryfe, R., Kim, H., Hsieh, E. T. K., Aronson, M. D., Holowaty, E. J., Bull, S. B., Redston, M., & Gallinger, S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001133420201 · Cited by 1,388
Self-citationRampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J. C., & Perucho, M. (1997) · Science · doi:10.1126/science.275.5302.967 · Cited by 1,326
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Cited by
Brenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Self-citationSargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Cunningham, D., Atkin, W., Lenz, H.-J., Lynch, H. T., Minsky, B., Nordlinger, B., & Starling, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60353-4 · Cited by 1,351
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
A clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 971
Milestones of Lynch syndrome: 1895–2015
Lynch, H. T., Snyder, C. L., Shaw, T. G., Heinen, C. D., & Hitchins, M. P. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3878 · Cited by 810
Genetic prognostic and predictive markers in colorectal cancer
Walther, A., Johnstone, E., Swanton, C., Midgley, R., Tomlinson, I., & Kerr, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2645 · Cited by 705
Zhao, P., Li, L., Jiang, X., & Li, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0738-1 · Cited by 682
Hutchins, G., Southward, K., Handley, K., Magill, L., Beaumont, C., Stahlschmidt, J., Richman, S., Chambers, P., Seymour, M., Kerr, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1366 · Cited by 681
Baretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 556
Győrffy, B. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100625 · Cited by 464
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
“Patients with tumors characterized by high microsatellite instability (MSI) have been suggested to respond better to irinotecanbased chemotherapy, [210, 211] but a recent meta-analysis failed to show any predictive value of MSI status in relation to treatment response [212].”
BackgroundColorectal cancer tumour markers and biomarkers: Recent therapeutic advances
Lech, G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i5.1745 · Cited by 419
Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer
Kawakami, H., Zaanan, A., & Sinicrope, F. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0348-2 · Cited by 418
Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival
Phipps, A. I., Limburg, P. J., Baron, J. A., Burnett-Hartman, A. N., Weisenberger, D. J., Laird, P. W., Sinicrope, F. A., Rosty, C., Buchanan, D. D., Potter, J. D., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.038 · Cited by 401
Gray, R. G., Quirke, P., Handley, K., Lopatin, M., Magill, L., Baehner, F. L., Beaumont, C., Clark-Langone, K. M., Yoshizawa, C. N., Lee, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8732 · Cited by 380
Chang, D. T., Pai, R. K., Rybicki, L. A., Dimaio, M. A., Limaye, M., Jayachandran, P., Koong, A. C., Kunz, P. A., Fisher, G. A., Ford, J. M., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.61 · Cited by 352
Colorectal cancer molecular biology moves into clinical practice
Pritchard, C. C., & Grady, W. M. (2011) · Gut · doi:10.1136/gut.2009.206250 · Cited by 344
Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0213 · Cited by 343
Labianca, R., Nordlinger, B., Beretta, G. D., Brouquet, A., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq168 · Cited by 340
Huijbers, A., Tollenaar, R. A. E. M., v Pelt, G. W., Zeestraten, E. C. M., Dutton, S., McConkey, C. C., Domingo, E., Smit, V. T. H. B. M., Midgley, R., Warren, B. F., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds246 · Cited by 337
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Genetics, diagnosis and management of colorectal cancer (Review)
DE ROSA, M., PACE, U., REGA, D., COSTABILE, V., DURATURO, F., IZZO, P., & DELRIO, P. (2015) · Oncology Reports · doi:10.3892/or.2015.4108 · Cited by 317
Sinicrope, F. A., & Sargent, D. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1469 · Cited by 309
Immunotherapy, Inflammation and Colorectal Cancer
Lichtenstern, C. R., Ngu, R. K., Shalapour, S., & Karin, M. (2020) · Cells · doi:10.3390/cells9030618 · Cited by 294
Des Guetz, G., Schischmanoff, O., Nicolas, P., Perret, G.-Y., Morere, J.-F., & Uzzan, B. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.018 · Cited by 291
Microsatellite instability in colorectal cancer
IACOPETTA, B., GRIEU, F., & AMANUEL, B. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01335.x · Cited by 289
Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H. L., Wong, S. F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu100 · Cited by 288
Cancer immunology—analysis of host and tumor factors for personalized medicine
Ogino, S., Galon, J., Fuchs, C. S., & Dranoff, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.122 · Cited by 284
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
Roth, A. D., Delorenzi, M., Tejpar, S., Yan, P., Klingbiel, D., Fiocca, R., d'Ario, G., Cisar, L., Labianca, R., Cunningham, D., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs427 · Cited by 284
Sinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 279
Self-citationEmerging therapeutic targets in endometrial cancer
Dedes, K. J., Wetterskog, D., Ashworth, A., Kaye, S. B., & Reis-Filho, J. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.216 · Cited by 270
Ogino, S., Shima, K., Meyerhardt, J. A., McCleary, N. J., Ng, K., Hollis, D., Saltz, L. B., Mayer, R. J., Schaefer, P., Whittom, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2246 · Cited by 267
Self-citationNCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 255
Halpern, N., Goldberg, Y., Kadouri, L., Duvdevani, M., Hamburger, T., Peretz, T., & Hubert, A. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s126905 · Cited by 23
Metadata
- Authors
- Bertagnolli, M. M., Niedzwiecki, D., Compton, C. C., Hahn, H. P., Hall, M., Damas, B., Jewell, S. D., Mayer, R. J., Goldberg, R. M., Saltz, L. B., Warren, R. S., & Redston, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-04-10
- Volume
- 27
- Issue
- 11
- Pages
- 1814-1821
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160550688
- Cited by
- 364
- References
- 33
- FWCI
- 32.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.